Search research articles
Contact Us
Filters
Showing results (211-220 of 308) with videos related to
Page
of 31
Sort By:
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
April 22, 2017
Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis
Seok-Jo Kim, Paul Cheresh, Mesut Eren, et al.
Bone Research
|
May 3, 2019
DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease
Corey Dussold, Claire Gerber, Samantha White, et al.
Scientific Reports
|
May 18, 2017
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Alexander Grabner, Karla Schramm, Neerupma Silswal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
August 26, 2019
Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD
Daniel Edmonston, Daniel Wojdyla, Rupal Mehta, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
March 13, 2024
Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study
Simon Hsu, Nisha Bansal, Michelle Denburg, et al.
Journal of the American Society of Nephrology : JASN
|
January 3, 2024
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial
Kalani L Raphael, Ronit Katz, Brett Larive, et al.
Stroke
|
March 10, 2016
Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study
Clinton B Wright, Nirav H Shah, Armando J Mendez, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 8, 2009
Klotho variants and chronic hemodialysis mortality
David J Friedman, Maryam Afkarian, Hector Tamez, et al.
Journal of Hepatology
|
November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.
Journal of the American Society of Nephrology : JASN
|
May 14, 2015
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD
Tamara Isakova, Joachim H Ix, Stuart M Sprague, et al.
Page
of 31
Search research articles
Search
Showing results (211-220 of 308) with videos related to
Sort By:
Page
of 31
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
April 22, 2017
Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis
Seok-Jo Kim, Paul Cheresh, Mesut Eren, et al.
Bone Research
|
May 3, 2019
DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease
Corey Dussold, Claire Gerber, Samantha White, et al.
Scientific Reports
|
May 18, 2017
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Alexander Grabner, Karla Schramm, Neerupma Silswal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
August 26, 2019
Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD
Daniel Edmonston, Daniel Wojdyla, Rupal Mehta, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
March 13, 2024
Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study
Simon Hsu, Nisha Bansal, Michelle Denburg, et al.
Journal of the American Society of Nephrology : JASN
|
January 3, 2024
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial
Kalani L Raphael, Ronit Katz, Brett Larive, et al.
Stroke
|
March 10, 2016
Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study
Clinton B Wright, Nirav H Shah, Armando J Mendez, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 8, 2009
Klotho variants and chronic hemodialysis mortality
David J Friedman, Maryam Afkarian, Hector Tamez, et al.
Journal of Hepatology
|
November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.
Journal of the American Society of Nephrology : JASN
|
May 14, 2015
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD
Tamara Isakova, Joachim H Ix, Stuart M Sprague, et al.
Page
of 31